Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Sterol carrier protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sterol carrier proteins (also known as nonspecific lipid transfer proteins) is a family of proteins that transfer steroids and probably also phospholipids and gangliosides between cellular membranes. These proteins are different from plant nonspecific lipid transfer proteins but structurally similar to small proteins of unknown function from Thermus thermophilus.
Conjugation process of bacterial polysaccharides to carrier proteins
ActiveUS8753645B2Antibacterial agentsBacterial antigen ingredientsBacteroidesStreptococcus pneumoniae
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Sterol Carrier Protein-2 Inhibitors for Lowering Cholesterol and Triglyceride Levels in Mammals
InactiveUS20080194658A1Lowering serum total cholesterol concentrationLowering serum low density lipoprotein cholesterol concentrationBiocideOrganic active ingredientsHydrobromideSerum ige
Methods of treating high serum levels of total cholesterol, low density lipoprotein and triglycerides in a mammal by administering therapeutically effective doses of N-(4-{[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]amino}phenyl)acetamide or a salt thereof such as a hydrochloride or hydrobromide salt.
Owner:ZAMA JAPAN
Monoclonal antibody of hepatitis B virus X protein and use thereof
The invention relates to a monoclonal antibody of hepatitis B virus X protein (HBx), which is characterized by having specificity reaction to N-end epitope or C-end epitope of HBx, but having no reaction to keyhole limpet hemocyanin (KLH) of carrier protein and other expressed proteins of hepatitis B virus (HBV). The preparation method of the monoclonal antibody comprises the steps of: fusing N-end and C-end antigen epitope polypeptides of HBx respectively with mice immunized with KLH in crosslinking way, and myeloma cells and screening to obtain the monoclonal antibody. The monoclonal antibody can be used for various immunodetection reagents and directed therapeutic drugs of HBx protein or HBx antibody and applied to diagnosis and treatment of diseases such as hepatitis b virus (HBV) infection, hepatocellular carcinoma (HCC) and the like.
Owner:王虹
Escherichia coli t7 expression vector, vectors for the co-expression and co-purification of recombinant peptides in/with carrier proteins, use of expression vectors for obtaining complexes with multiple antigens and immonomodulators
InactiveUS20180135060A1Increase productionAntibacterial agentsAntibody mimetics/scaffoldsEscherichia coliAmpicillin
The present invention relates to a vector for the expression of recombinant proteins, antigens, pathogen-like particles and immunogenic complexes, said vector (pMRKA vector) being produced by modifying the plasmids containing the gene sequence of the T7 promoter of E. coli, this modification being mainly characterized by the substitution of the ampicillin-resistance gene by the kanamycin-resistance gene, and by the insertion of the par sequence (partition sequence which determines the efficient segregation of the plasmids in daughter cells during cell division). Also provided are expression vectors based on the pMRKA plasmid, which additionally comprise at least one of the gene sequences of the exosome of P. abyssi, which vectors are designated pMRKA-EXO, pMRKA-RING and pSUMAC. The invention also provides the vectors additionally comprising gene sequences with immunomodulatory or immunoregulatory activity, preferably the pMRKA-Z-Z-EXO and pMRKA-Z-Z-RING vectors. Other aspects of the invention include the method for producing said expression vectors and the use of the obtained vectors.
Owner:OURO FINO SAUDE ANIMAL
Conjugation process of bacterial polysaccharides to carrier proteins
ActiveUS20120321660A1Size of it can retainAntibacterial agentsBacterial antigen ingredientsBacteroidesStreptococcus pneumoniae
Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Carrier protein of bacterial polysaccharide conjugate vaccine and application thereof
ActiveCN106511994AUniform polysaccharide binding siteQuality controllableAntibacterial agentsImmunoglobulins against bacteriaConjugate vaccineCarrier protein
The invention discloses a bacterial polysaccharide O-glycosylation modified recombinant cholera toxin B subunit fusion protein and an application thereof. The present invention provides a conjugate of polysaccharide and protein which is coupled by the bacterial polysaccharide and recombinant cholera toxin B subunit fusion protein. The bacterial polysaccharide is connected with the glycosylation sites of the recombinant cholera toxin B subunit fusion protein in the form of O-glucosidic bond. The experiment indicates that the preparation of the bacterial polysaccharide protein conjugate vaccine from O-glycosylation modified recombinant cholera toxin B subunit fusion protein can enhance the ability of inducing animals to generate anti-polysaccharide antibodies, avoid miscellaneous problems of pathogen culture, enhance the vaccine homogeneity and production efficiency, and reduce the vaccine preparation cost, therefore possessing wide application prospect.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Preparations and uses of streptomycin-carrier protein coupled product and streptomycin antibody
The invention discloses a coupling product of streptomycin and carrier protein, and a preparation method of a streptomycin antibody and an application thereof, which relate to a coupling method of the carrier protein such as keyhole limpet hemocyanin, human serum albumin, cow serum albumin, ovalbumin and the like with streptomycin, and immune BALB / C mouse spleen cells are fused with SP2 / 0 mouse myeloma cells by streptomycin immunogens coupled with the carrier protein, and the streptomycin coupled with the carrier protein is used as a coating antigen for screening positive hybridoma and hybridoma that can steady passage and excrete anti-specificity streptomycin monoclonal antibody can be obtained by the cell clone, and ascites monoclonal antibody is prepared. The prepared monoclonal antibody is used for building a direct competition ELISA method with high specificity, sensitivity and accuracy to the streptomycin and immunity colloidal gold test strips. The coupling of the streptomycin and the carrier protein and the preparation method of the streptomycin monoclonal antibody can provide services for detecting streptomycin residue in foods quickly.
Owner:ZHEJIANG UNIV
Synthetic method of urethane artificial antigen
InactiveCN102718861AReduced shieldingAccurate dosageOvalbuminSerum albuminEthyl chloroformateChemical synthesis
The invention provides a synthetic method of urethane artificial antigen. The urethane artificial antigen is prepared by the following steps of: 1, preparation of beta-alanine and ethyl chloroformate; 2, synthesis of hapten; 3, purification of hapten; 4, preparation of 1-(3-dimethylamino propyl)-3-ethyl carbodiimide solution; 5, synthesis of artificial antigen; 6, dialysis and detection of artificial antigen; and 7, calculation of quantity of different used carrier proteins. According to the synthetic method, the shielding effect of the protein to the hapten obtained by chemical synthesis is low, therefore, high-titer polyclonal antibody can be generated in an immune animal, and the molecular weight can be detected during synthesizing the artificial antigen, and the coupling ratio can be calculated, and the quantity of used raw materials for synthesizing is precise.
Owner:ZHEJIANG FORESTRY UNIVERSITY
Carrier protein, recombinant expression vector, exosome and preparation method and application of exosome
InactiveCN109293745AEfficient entryEfficient expressionAntibody mimetics/scaffoldsDepsipeptidesSterol carrier proteinForeign protein
The invention provides carrier protein, recombinant expression vector, an exosome and a preparation method and application of the exosome. Foreign protein can be carried into the exosome efficiently through fusion of the carrier protein with the foreign protein. Through the recombinant expression vector, a to-be-expressed foreign protein peptide fragment gene sequence is inserted into polyclonal sites of the recombinant expression vector, so that efficient and directed expression of the foreign protein in the cell exosome is achieved; meanwhile, the invention also provides the preparation method of the exosome for carrying the foreign protein, foreign gene can be brought into the exosome effectively, and simple and easy operation, a stable process and good applicability are achieved; and the exosome prepared by using the preparation method contains the foreign protein, has good cell permeability and highly efficiency of cell transfection, the activity and efficacy of the foreign protein can be developed at the same time, and a broad application prospect is achieved.
Owner:JINAN UNIVERSITY
Bacterial polysaccharide protein conjugate vaccine using hepatitis B surface antigen as carrier protein and preparation method of bacterial polysaccharide protein conjugate vaccine
InactiveCN104383532AAddressing Immunization IssuesPlay a role in preventionAntibacterial agentsAntiviralsAntigenConjugate vaccine
The invention discloses a bacterial polysaccharide protein conjugate vaccine using a hepatitis B surface antigen as carrier protein and a preparation method of the bacterial polysaccharide protein conjugate vaccine. According to the vaccine, protein is the hepatitis B surface antigen, and a bacterial polysaccharide is selected from any one or more of a haemophilus influenza type b polysaccharide, group A, group C, group Y and group W135 meningococcal polysaccharides, a salmonella typhi type Vi polysaccharide, a group B streptococcus type Ia polysaccharide and the like, pneumococcus serotype type 1, 2 and the like, and salmonella paratyphi type A or salmonella paratyphi type B. Animal experiments show that the antibody positive conversion rates of the bacterial polysaccharide and the hepatitis B surface antigen in the vaccine are both more than 85%, so that the vaccine is relatively high in antibody positive conversion rate; carrier protein plays a role in transforming the bacterial polysaccharide from a T-cell-independent antigen into a T-cell-dependent antigen, and also can be used for preventing diseases caused by hepatitis B virus; and by adopting the bacterial polysaccharide protein conjugate vaccine disclosed by the invention, the problem of performing immunization inoculation on infants and young children under 2 years old can be solved, the function of one injection with multiple immune effects also can be achieved, and the use crowd and coverage rate of the vaccine can be expanded.
Owner:云南沃森生物技术股份有限公司
Conjugate, and preparation and use thereof
ActiveCN101475640ASmall side effectsImprove securityCarrier-bound antigen/hapten ingredientsPharmaceutical non-active ingredientsEpitheliumAdjuvant
The invention discloses a coupling object. The coupling object is obtained through the coupling of at least one protein in the four proteins of a recombined human epidermal growth factor and a recombined epidermal growth factor mutant with a carrier protein. The amino acid sequence of the recombined human epidermal growth factor is shown by the No.2 sequence in a sequence list. The recombined epidermal growth factor mutant can be one of the following proteins: 1)the protein obtained through the deletion of the No.53 arginine in the No.2 sequence in the sequence list; 2) the protein obtained through the deletion of the No.53 arginine and No.52 leucine in the No.2 sequence in the sequence list; and 3) the protein obtained through the addition of methionine before the No.1 asparagine in the No.2 sequence in the sequence list. The coupling object can be used as a vaccine for the active treatment of an epithelium sourced tumor after being mixed with an adjuvant. Results show that the vaccine can induct the high level antibodies in a mouse; the highest antibody titer reaches 1:20,000; and the prolonging rate of the survival period of the mouse reaches 69.4 percent.
Owner:BIOTECH PHARMA CO LTD +3
Glycosylated polypeptide, conjugate of glycosylated polypeptide and carrier protein, as well as preparation method and application of glycosylated polypeptide
InactiveCN104558112AQuick checkEasy to detectBiological testingHybrid peptidesSterol carrier proteinAcyl carrier protein
The invention provides glycosylated polypeptide, a conjugate of the glycosylated polypeptide and carrier protein, as well as a preparation method and application of the glycosylated polypeptide. The glycosylated polypeptide has a sequential structure of Glyco-Val-His-Leu-Thr-Pro-Tyr-Ryr-Cys; the conjugate of the glycosylated polypeptide and the carrier protein is a product generated after the tail end Crs of the glycosylated polypeptide is coupled with the carrier protein (such as bovine serum albumin, myohemoglobin or hemocyanin); the glycosylated polypeptide or the conjugate of the glycosylated polypeptide and the carrier protein can be used for replacing an expensive pure human glycosylated hemoglobin antigen product to prepare a chromatographic testing bar (testing paper bar); the chromatographic testing b bar can be used for rapidly, accurately, quantitatively, simply and conveniently detecting the glycosylated hemoglobin in the whole blood.
Owner:BEIJING YICHENG BIOELECTRONICS TECHNOLOGY COMPANY
Preservation method of cotton bollworm sterol carrier protein-2
ActiveCN107177619AMeet demandRapid cessation of metabolic activityBacteriaMicroorganism based processesCotton bollwormDissolution
The invention relates to the field of biotechnology and in particular to a preservation method of cotton bollworm sterol carrier protein-2. The preservation method of the cotton bollworm sterol carrier protein-2 designed by the invention comprises the following steps: (1) constructing genetic engineering bacteria; (2) abundantly expressing target protein; (3) digging 10-20g thallus with a medicine spoon each time, placing the thallus in liquid nitrogen, freezing the thallus into solid spherical bacterium balls under the action of rapidly cooling the liquid nitrogen, and after the obtained thallus is frozen into a plurality of bacterium balls by the liquid nitrogen, placing all the bacterium balls in a refrigerator at the temperature of 80 DEG C below zero for preservation; and (4) according to the required protein quantity, taking a proper amount of the bacterium balls out of refrigerator with the temperature of 80 DEG C below zero per time, dissolving the bacterium balls into a buffer solution, enabling the bacterium balls to be sequentially subjected to cell disruption and protein purification after complete dissolution, and obtaining the target protein. The preservation method can ensure the content and the activity of the protein used in each test study to keep relatively consistent and also saves tedious procedure required for each induction culture.
Owner:HUBEI UNIV OF TECH
Fusion proteins of superfolder green fluorescent protein and use thereof
ActiveUS20180016310A1Antibody mimetics/scaffoldsCalcitoninsSterol carrier proteinAcyl carrier protein
The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.
Owner:SUZHOU KUNPENG BIOTECH
Cotton bollworm sterol carrier protein 2 inhibitor and virtual screening method thereof
InactiveCN106106481AShorten screening timeImprove screening efficiencyChemical property predictionBiocideAgricultural scienceOrder Lepidoptera
The invention belongs to the technical field of agricultural biotechnologies, and relates to establishment of a cotton bollworm sterol carrier protein 2 (SCP-2) small-molecule inhibitor virtual screening method. The method comprises the following steps: according to structural data of cotton bollworm sterol carrier protein 2 (SCP-2), analyzing a key amino acid residue so as to confirm a binding pocket; screening, scoring and calculating binding free energy by using molecular docking software; performing structure clustering and visual analysis on an obtained compound, thereby obtaining a small-molecule inhibitor for SCP-2 protein. The small-molecule inhibitor can be applied to screening, study and development of novel environmental-friendly pesticides for multiple agricultural pests of lepidoptera as the main target.
Owner:HUBEI UNIV OF TECH
Allogenic animal serum albumin as carrier protein for preparation of semiantigen-antibody
The present invention relates to a preparation method for a semi-antigen antibody. In details, the present invention discloses a preparation method for semi-antigen antibody by means of serum albumin of various animals as the carriers. According to the preparation method, first of all, semi-antigens of serum albumin of various animals are coupled into full antigens; and then the full antigens are used to generate antibodies. The serum albumin is protein which exists in the animal body since the embryo development. The immune cells already have immune no-response and the serum albumin is of no allotype or co-phenotype allele. The serum albumin does not vary from animal to animal and takes a large amount in the blood. Serum albumin can be easily obtained and the purifying process is simple. Therefore, the semi-antigen antibody prepared through the method is of higher value and better specificity.
Owner:SHANGHAI KEXIN BIOTECH
Fusion proteins of superfolder green fluorescent protein and use thereof
The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.
Owner:SUZHOU KUNPENG BIOTECH
Cell strain with sterol carrier protein (SCP) stable transformation of prodenia litura and preparation method and application of cell strain
InactiveCN106480094AEffective combinationGrowth arrestCompound screeningApoptosis detectionEscherichia coliDna transfection
The invention discloses a preparation method of a cell strain with sterol carrier protein (SCP) stable transformation of prodenia litura. The preparation method sequentially includes the steps of 1), cloning cDNA (complementary deoxyribonucleic acid) of SCP (single-cell protein)-2 gene from prodenia litura; 2), cloning the cDNA of the SCP-2 encoded protein into pcDNA5 / FRT plasmid to form recombined pcDNA5 / FRT-SCP2 plasmid; 3), applying the pcDNA5 / FRT-SCP2 plasmid to transform colon bacillus and obtaining transformed colon bacillus via cultivation; 4), extracting recombined plasmid DNA from the transformed colon bacillus and performing purification; 5), transfecting Chinese hamster ovary cells with purified and recombined pcDNA5 / FRT-SCP2 plasmid DNA; 6), selecting transfected CHO cells in a culture medium containing antibiotic hygromycinB and performing continuous subculture to obtain the cell strain. The invention aims to provide the cell strain with SCP stable transformation of the prodenia liture, the preparation method of the cell strain and an application of the cell strain. The cell strain has the advantages of high screening accuracy, simpleness in operation and accuracy in result.
Owner:SOUTH CHINA NORMAL UNIVERSITY
Preparation for self-protein used as carrier protein for hapten-antibody
InactiveCN101165069ADoes not affect healthImmunoglobulins against animals/humansForeign proteinSterol carrier protein
The present invention relates to hapten antibody preparing process, and is especially the process of first preparing complete antigen through coupling animal's autologous protein to hapten and subsequent preparing antibody through immunizing animal with the complete antigen. The antibody preparing process has no introduced foreign protein, body produced antibody targeting to the small molecular weight compound and small peptide hapten, and no antibody to autologous protein. Therefore, the prepared hapten antibody prepared with autologous protein as carrier protein has high valence and high specificity.
Owner:SHANGHAI KEXIN BIOTECH
Fusion protein for treating intestinal diseases
ActiveUS20190241639A1Weaken the chain exchange phenomenon characteristic of the IgG4 isotypeExtended half-lifePeptide/protein ingredientsAntibody mimetics/scaffoldsIntestinal structureDisease
The invention provides fusion proteins for treating an intestinal disease, having a structure as follows: R-L-P, wherein R is a GLP-2 receptor agonist; L is a peptide linker; and P is a long-acting carrier protein. The fusion protein provided by the invention has significant bioactivities and in vitro stability.
Owner:ZHEJIANG DOER BIOLOGICS CO LTD
Immunogenic composition
ActiveUS20150224204A1Improving immunogenicityInduce and enhance immune responseAntibacterial agentsNervous disorderSterol carrier proteinCarrier protein
The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype Ia conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein; d) a conjugate that is a capsular saccharide from GBS serotype II conjugated to a carrier protein; and e) a conjugate that is a capsular saccharide from GBS serotype V conjugated to a carrier protein.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
A vaccine composition and uses thereof
The present invention provides a vaccine composition comprising: (i) an adjuvant; and (ii) at least one fusion peptide conjugated to a carrier protein, wherein the carrier protein is the diphtheria toxin variant CRM-197 (GenBank Accession No. and wherein the at least one fusion peptide comprises two or more non- contiguous B cell epitopes of Her2 / neu selected from the group consisting of SEQ ID Nos:1-7 and 15-60 and amino acid sequences that have at least 85% identity to any of the foregoing. The present invention also extends to pharmaceutical compositions and methods of using the vaccine and / or pharmaceutical compositions, as herein described, for the treatment or prevention of a cancer characterised by the expression or over-expression of Her2 / neu in a patient in need thereof.
Owner:BIOLIFE SCI QLD
Monoclonal antibody for hippuric acid antigen
InactiveUS20090227777A1Higher competitive inhibitionEngineer specificityImmunoglobulins against animals/humansRecombinant DNA-technologyMetaboliteProtein L
Owner:IND ACADEMIC CORP FOUND YONSEI UNIV +1
A kind of inhibitor of cotton bollworm sterol carrier protein 2 and its virtual screening method
InactiveCN106106481BShorten screening timeImprove screening efficiencyChemical property predictionBiocideHelicoverpaAgricultural science
Owner:HUBEI UNIV OF TECH
Monoclonal antibody for hippuric acid antigen
InactiveUS7816498B2Engineer specificityEngineer affinityImmunoglobulins against animals/humansRecombinant DNA-technologyCross linkerCarrier protein
Owner:IND ACADEMIC COOP FOUND DANKOOK UNIV +1
Preservation method of sterol carrier protein 2 of cotton bollworm
ActiveCN107177619BMeet demandRapid cessation of metabolic activityBacteriaMicroorganism based processesBiotechnologyCotton bollworm
Owner:HUBEI UNIV OF TECH
Verticillium dahliae adp-atp carrier protein disease course key target gene and its interference carrier and application
ActiveCN105177024BImprove disease resistanceFermentationVector-based foreign material introductionDiseaseGene silencing
Owner:THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI
Cotton Sterol Carrier Protein Gene and Its Application
ActiveCN104894141BHigh elongationImprove qualityFermentationVector-based foreign material introductionFiberAgricultural science
A sterol carrier protein gene of cotton and applications thereof are disclosed. The sterol carrier protein gene is Gh SCP2D. The ORF sequence of the gene is shown as SEQ ID NO.1. The genomic sequence of the gene is shown as SEQ ID NO.2. Upland cotton is subjected to transgenic research by constructing a plant antisense expression vector, and expression analysis shows that expression of the gene is obviously inhibited, a phenotype of reduced velvet length is shown in transgenic plant, and the sucrose content is obviously reduced, so that the sterol carrier protein gene Gh SCP2D can be applied in sucrose transportation modification and cotton fiber elongation modification in cotton fiber development processes.
Owner:NANJING AGRICULTURAL UNIVERSITY
Hydrophobically modified polyethylenimines and their use as protein carriers
InactiveCN103059295BStrong protein bindingIntroduce an immune responseViral antigen ingredientsAntiviralsAntigenProtein insertion
Owner:SHANGHAI JIAO TONG UNIV +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com